IP Library Patent Application 11984931
Patent Application
App. No. 11/984,931

Rubrofusarin glycoside-containing composition

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/984,931
Abstract

There is provided an oral composition capable of stimulating intracellular biosynthesis of glutathione in order to maintain in-vivo (i.e., in tissues and cells) glutathione level at a high level, by adding an active ingredient other than an amino acid precursor from a viewpoint of increasing intracellular glutathione synthesis, as a method which is an alternative or can be combined with a method of supplying an amino acid precursor to be used in glutathione biosynthesis. The oral composition is used for maintaining or increasing intracellular glutathione level and contains at least one rubrofusarin glycoside in an amount that is effective for increasing the intracellular glutathione.

Claims (10)

1 - 15 . (canceled)

16 . A method for maintaining or increasing the intracellular glutathione level in a person or animal, comprising administering at least one rubrofusarin glycoside in an amount effective for increasing the intracellular glutathione level in said person or animal.

17 . The method according to claim 16 , wherein said at least one rubrofusarin glycoside is administered in the form of an extract from a Cassia plant or a Senna plant containing rubrofusarin glycosides.

18 . The method according to claim 17 , wherein the plant containing rubrofusarin glycoside is Cassia or Senna.

19 . The method according to any one of claims 16 to 18 , wherein all or the most part of the rubrofusarin glycoside comprises rubrofusarin gentiobioside.

20 . The method according to claim 16 , wherein said at least one rubrofusarin glycoside is administered in combination with a precursor for intracellular glutathione biosynthesis and optionally a vitamin C component.

21 . The method according to claim 20 , wherein the combination of the rubrofusarin glycoside and the precursor for intracellular glutathione biosynthesis produces a synergistic effect in the increment of intracellular glutathione level.

22 . The method according to claim 20 or claim 21 , wherein the precursor for intracellular glutathione biosynthesis is selected from the group consisting of egg white, egg membrane, milk whey, yeast protein, vegetable protein, soy bean, L-cysteine, and L-methionine.

23 . The method according to claim 22 , wherein the precursor for intracellular glutathione biosynthesis is combined in an amount of 0.1 wt % to 10 wt % in terms of L-cysteine or L-methionine on solid basis.

24 . The method according to claim 16 , wherein the maintaining or increasing of the intracellular glutathione level is effective for maintaining and improving functions of the liver, brain, vision, or immune system; mitigating fatigue; suppressing damage to organs involved in enhanced detoxification metabolism; reducing risk of cancer; maintaining and activating the immune system; recovering from muscle fatigue; preventing dullness of the skin; preventing lifestyle-related diseases; preventing smoking-induced disorders; treating chronic fatigue syndrome due to AIDS; or preventing aging, all of which is related to oxidative stress in an animal or person.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2009
From: SUNTORY LIMITED
To: SUNTORY HOLDINGS LIMITED
Reel/Frame 022653/0665 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TITLE TO READ PATIENT DIRECTED THERAPY CONTROL PREVIOUSLY RECORDED ON REEL 020373 FRAME 0265. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 31, 2008
From: PANKEN, ERIC J.; DENISON, TIMOTHY J.; MOLNAR, GREGORY F.
To: MEDTRONIC, INC.
Reel/Frame 020450/0197 →